![Researcher in a biotech lab](/web/20170122065700im_/http://www.smh.com.au/content/dam/images/g/s/q/k/o/y/image.related.wideLandscape.460x259.gtm71i.png/1485053728294.jpg)
Biotech set to regain favour after recent thrills and spills
The last few months have been ones to forget for biotech investors with a rotation of funds out of high PE stocks in many markets which has left stocks in the sector well down on their 2016 highs